- Home
- RVNC vs SIGA Comparison
RVNC vs SIGA Comparison
Compare RVNC & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVNC
- SIGA
- Stock Information
- Founded
- RVNC 1999
- SIGA 1995
- Country
- RVNC United States
- SIGA United States
- Employees
- RVNC N/A
- SIGA N/A
- Industry
- RVNC Biotechnology: Pharmaceutical Preparations
- SIGA Biotechnology: Pharmaceutical Preparations
- Sector
- RVNC Health Care
- SIGA Health Care
- Exchange
- RVNC Nasdaq
- SIGA Nasdaq
- Market Cap
- RVNC 599.6M
- SIGA 551.0M
- IPO Year
- RVNC 2014
- SIGA 1997
- Fundamental
- Price
- RVNC $5.78
- SIGA $7.63
- Analyst Decision
- RVNC Buy
- SIGA
- Analyst Count
- RVNC 10
- SIGA 0
- Target Price
- RVNC $10.86
- SIGA N/A
- AVG Volume (30 Days)
- RVNC 1.6M
- SIGA 422.0K
- Earning Date
- RVNC 11-19-2024
- SIGA 11-07-2024
- Dividend Yield
- RVNC N/A
- SIGA 7.83%
- EPS Growth
- RVNC N/A
- SIGA 197.35
- EPS
- RVNC N/A
- SIGA 1.17
- Revenue
- RVNC $251,178,000.00
- SIGA $172,956,776.00
- Revenue This Year
- RVNC $20.36
- SIGA $16.98
- Revenue Next Year
- RVNC $31.66
- SIGA $16.49
- P/E Ratio
- RVNC N/A
- SIGA $6.56
- Revenue Growth
- RVNC 40.23
- SIGA 76.90
- 52 Week Low
- RVNC $2.30
- SIGA $4.26
- 52 Week High
- RVNC $9.75
- SIGA $12.83
- Technical
- Relative Strength Index (RSI)
- RVNC 56.47
- SIGA 59.91
- Support Level
- RVNC $5.67
- SIGA $6.80
- Resistance Level
- RVNC $5.97
- SIGA $7.51
- Average True Range (ATR)
- RVNC 0.19
- SIGA 0.36
- MACD
- RVNC 0.06
- SIGA 0.13
- Stochastic Oscillator
- RVNC 78.01
- SIGA 76.87
About RVNC Revance Therapeutics Inc.
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.